Hepatitis Monthly

Published by: Kowsar

Estrogen Receptor Alpha Expression and Liver Fibrosis in Chronic Hepatitis C Virus Genotype 1b: A Clinicopathological Study

Mustafa Cengiz 1 , * , Seren Ozenirler 2 and Guldal Yılmaz 3
Authors Information
1 Department of Gastroenterology, Dr. A.Y. Ankara Oncology Training and Research Hospital, Ankara, Turkey
2 Department of Gastroenterology, Faculty of Medicine, Gazi University, Ankara, Turkey
3 Deparment of Pathology, Faculty of Medicine, Gazi University, Ankara, Turkey
Article information
  • Hepatitis Monthly: September 01, 2014, 14 (9); e21885
  • Published Online: September 24, 2014
  • Article Type: Research Article
  • Received: July 9, 2014
  • Revised: September 6, 2014
  • Accepted: September 7, 2014
  • DOI: 10.5812/hepatmon.21885

To Cite: Cengiz M, Ozenirler S, Yılmaz G. Estrogen Receptor Alpha Expression and Liver Fibrosis in Chronic Hepatitis C Virus Genotype 1b: A Clinicopathological Study, Hepat Mon. 2014 ; 14(9):e21885. doi: 10.5812/hepatmon.21885.

Copyright © 2014, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999; 340(16): 1228-33[DOI][PubMed]
  • 2. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349(9055): 825-32[PubMed]
  • 3. Feray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology. 1995; 108(4): 1088-96[PubMed]
  • 4. Garcia-Samaniego J, Soriano V, Castilla J, Bravo R, Moreno A, Carbo J, et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group. Am J Gastroenterol. 1997; 92(7): 1130-4[PubMed]
  • 5. Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Kawakami Y, Akazawa K, et al. Transmission of hepatitis C virus by health care workers in a rural area of Japan. Am J Gastroenterol. 1995; 90(5): 794-9[PubMed]
  • 6. Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N, et al. Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med. 1998; 158(2): 177-81[PubMed]
  • 7. Shimizu I, Ito S. Protection of estrogens against the progression of chronic liver disease. Hepatol Res. 2007; 37(4): 239-47[DOI][PubMed]
  • 8. Li X, Huang J, Yi P, Bambara RA, Hilf R, Muyan M. Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways. Mol Cell Biol. 2004; 24(17): 7681-94[DOI][PubMed]
  • 9. McInerney EM, Weis KE, Sun J, Mosselman S, Katzenellenbogen BS. Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology. 1998; 139(11): 4513-22[DOI][PubMed]
  • 10. Inoue H, Shimizu I, Lu G, Itonaga M, Cui X, Okamura Y, et al. Idoxifene and estradiol enhance antiapoptotic activity through estrogen receptor-beta in cultured rat hepatocytes. Dig Dis Sci. 2003; 48(3): 570-80[PubMed]
  • 11. Yasuda M, Shimizu I, Shiba M, Ito S. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology. 1999; 29(3): 719-27[DOI][PubMed]
  • 12. Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, Reiser H, et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology. 2008; 48(6): 1761-8[DOI][PubMed]
  • 13. Watashi K, Inoue D, Hijikata M, Goto K, Aly HH, Shimotohno K. Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B. J Biol Chem. 2007; 282(45): 32765-72[DOI][PubMed]
  • 14. Lacort M, Leal AM, Liza M, Martin C, Martinez R, Ruiz-Larrea MB. Protective effect of estrogens and catecholestrogens against peroxidative membrane damage in vitro. Lipids. 1995; 30(2): 141-6[PubMed]
  • 15. Lu G, Shimizu I, Cui X, Itonaga M, Tamaki K, Fukuno H, et al. Antioxidant and antiapoptotic activities of idoxifene and estradiol in hepatic fibrosis in rats. Life Sci. 2004; 74(7): 897-907[PubMed]
  • 16. Bissell DM. Sex and hepatic fibrosis. Hepatology. 1999; 29(3): 988-9[DOI][PubMed]
  • 17. Wang YJ, Wang SS, Bickel M, Guenzler V, Gerl M, Bissell DM. Two novel antifibrotics, HOE 077 and Safironil, modulate stellate cell activation in rat liver injury: differential effects in males and females. Am J Pathol. 1998; 152(1): 279-87[PubMed]
  • 18. Kwan G, Neugarten J, Sherman M, Ding Q, Fotadar U, Lei J, et al. Effects of sex hormones on mesangial cell proliferation and collagen synthesis. Kidney Int. 1996; 50(4): 1173-9[PubMed]
  • 19. Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J Viral Hepat. 2000; 7(4): 250-7[PubMed]
  • 20. Kumada T, Toyoda H, Honda T, Kuzuya T, Katano Y, Nakano I, et al. Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan. Intervirology. 2006; 49(1-2): 112-8[DOI][PubMed]
  • 21. Furusyo N, Ogawa E, Sudoh M, Murata M, Ihara T, Hayashi T, et al. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J Hepatol. 2012; 57(6): 1186-92[DOI][PubMed]
  • 22. Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci. 2009; 54(6): 1317-24[DOI][PubMed]
  • 23. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology. 1994; 19(5): 1088-94[PubMed]
  • 24. Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5): 346-55[PubMed]
  • 25. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000; 132(4): 296-305[PubMed]
  • 26. Erkan G, Yilmaz G, Cengiz M, Degertekin CK, Akyol G, Ozenirler S. Lack of association of hepatic estrogen receptor-alpha expression with histopathological and biochemical findings in chronic hepatitis C. Pathol Res Pract. 2013; 209(11): 727-30[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments